Tech Company Financing Transactions
HOOKIPA Pharma Funding Round
On 2/27/2019, HOOKIPA Pharma secured $37.4 million in Series D funding from Redmile Group, Invus and Samsara BioCapital.
Transaction Overview
Company Name
Announced On
2/27/2019
Transaction Type
Venture Equity
Amount
$37,400,000
Round
Series D
Investors
Proceeds Purpose
The new funding will be primarily used to progress the clinical development of HOOKIPA's lead development programs, HB-101, a prophylactic cytomegalovirus vaccine candidate, currently in a Phase 2 clinical trial in patients awaiting kidney transplantation as well as HB-201 and HB-202, the Company's lead oncology product candidates, in development for the treatment of human papillomavirus-positive cancers.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
350 5th Ave. 7240
New York, NY 10118
USA
New York, NY 10118
USA
Phone
Website
Email Address
Overview
Hookipa Pharma Inc. (Nasdaq: HOOK) is a clinical stage company developing products to prevent and cure infectious diseases and cancer. With this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joern Aldag
Chief Financial Officer
Reinhard Kandera
Chief Medical Officer
Igor Matushansky
Chief Scientific Officer
Daniel Pinschewer
VP - Bus. Development
Anders Lilja
VP - Finance
Tony Melckenbeek
VP - R & D
Klaus Orlinger
Browse more venture capital transactions:
Prev: 2/27/2019: Lightstream venture capital transaction
Next: 2/27/2019: Lightmatter venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC transactions reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs